CVRx Inc
$ 7.22
-2.70%
29 Dec - close price
- Market Cap 189,237,000 USD
- Current Price $ 7.22
- High / Low $ 7.56 / 7.00
- Stock P/E N/A
- Book Value 1.84
- EPS -1.99
- Next Earning Report 2026-02-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.92 %
- 52 Week High 18.55
- 52 Week Low 4.30
About
CVRx Inc. is an innovative medical technology company specializing in implantable devices designed to treat chronic health issues, particularly hypertension and heart failure. The company's flagship product, Barostim Neo, utilizes sophisticated neuromodulation technology to effectively control blood pressure in patients who do not respond to traditional therapies. With a strong commitment to enhancing patient outcomes and responding to critical clinical needs, CVRx is strategically positioned within the cardiovascular sector, bolstered by a promising product pipeline and a focus on innovation, thus driving potential growth and value creation in the healthcare industry.
Analyst Target Price
$11.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-04 | 2025-05-08 | 2025-02-04 | 2024-10-29 | 2024-07-29 | 2024-04-30 | 2024-01-25 | 2023-10-26 | 2023-07-25 | 2023-04-27 | 2023-01-26 |
| Reported EPS | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 | -0.55 | -0.51 |
| Estimated EPS | -0.5 | -0.52 | -0.57 | -0.38 | -0.47 | -0.55 | -0.54 | -0.54 | -0.58 | -0.58 | -0.56 | -0.56 |
| Surprise | 0.01 | -0.05 | 0.04 | -0.05 | -0.1 | -0.1 | -0.5 | 0.1 | 0.15 | 0.02 | 0.01 | 0.05 |
| Surprise Percentage | 2% | -9.6154% | 7.0175% | -13.1579% | -21.2766% | -18.1818% | -92.5926% | 18.5185% | 25.8621% | 3.4483% | 1.7857% | 8.9286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.42 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVRX
2025-12-24 02:09:37
CVRx, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. (PT). A live webcast and archived version of the presentation will be available on the company's investor relations website. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its Barostim™ device approved for heart failure treatment.
2025-12-23 03:09:29
CVRx, Inc. announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT. A live webcast and archived version of the presentation will be available on the company's investor relations website. CVRx specializes in neuromodulation solutions for cardiovascular diseases, featuring Barostim™, an FDA-approved device for heart failure symptoms.
2025-12-22 23:09:35
CVRx has partnered with CentraCare - St. Cloud Hospital for the first Barostim device implants, aiming to provide a new therapeutic option for heart failure patients. This collaboration highlights CVRx's dedication to improving cardiovascular care and patient outcomes through innovative solutions. The Barostim device's growing clinical presence is also noted at other institutions, with upcoming billing updates in early 2026 expected to influence patient access and broader adoption of these therapies.
2025-12-22 08:30:00
CVRx, Inc. announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT. A live webcast and archived version of the presentation will be available on the company's investor relations website. CVRx specializes in neuromodulation solutions for cardiovascular diseases, with its Barostim™ device approved by the FDA for heart failure.
2025-12-20 00:10:17
CVRx celebrates a significant achievement as Los Robles Regional Medical Center successfully completes 25 Barostim implant surgeries, showcasing dedication to innovative therapy. The Barostim implant is recognized for its potential to improve treatment outcomes by interacting with the body's cardiovascular system. This milestone further builds on efforts to enhance cardiac care and anticipates a Jan 2026 Barostim billing update to broaden patient access and refine reimbursement practices.
2025-12-19 19:10:17
This article analyzes CVRX Inc. (NASDAQ: CVRX), highlighting weak sentiment across all horizons supporting a short bias. It details several AI-generated trading strategies including position, momentum breakout, and risk hedging, along with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
